Please login to the form below

Not currently logged in
Email:
Password:

Failure is Pfizer's opportunity

The surprise late-stage failure of Pfizer's experimental cardiovascular drug torcetrapib has put a rush on plans to reshape

The surprise failure in late-stage clinical trials of torcetrapib, Pfizer's experimental cardiovascular compound which was shown to prevent significantly fewer deaths than Lipitor, has compelled the company to accelerate its plans to transform itself into a more efficient, cheaper-running operation.

Pfizer's decision to cease all trials of torcetrapib was an unanticipated move that sent its share price downwards by around 12 per cent (approx ?12.1bn in market value) and led analysts to focus on the resulting `hole' left in the company's pipeline and potential future earnings. Torcetrapib was one of the firm's most promising and important products in development upon which it was relying to fill revenue gaps created by core products coming off patent, including Lipitor in 2010.

An analysis of the data from a 15,000-patient trial, ILLUMINATE, revealed that a greater number of deaths and cardiovascular events had occurred in the group receiving torcetrapib compared with those patients receiving Lipitor, the comparator compound in the study; 81 deaths versus 51. Pfizer was keen to point out that while torcetrapib, like Lipitor, affects the body's levels of cholesterol, the new findings do not throw up any fresh safety or efficacy issues related to Lipitor. The two drugs act differently.

However, the key impact for the company from the loss of torcetrapib is that it must act with intensified urgency to line up sufficient money-earning products that will bolster its near-term and mid-term futures. Healthy cash reserves and strong income from existing products for several more years makes an aggressive acquisitive and in-licensing period very likely.

ìPfizer's financial strength will enable it to continue to invest in a wide range of pipeline opportunities,î CEO Jeffrey Kindler said in a statement. ìIn addition, Pfizer will bring increased focus and emphasis to its business development and licensing efforts in order to identify new products and technologies that will supplement its pipeline.î

He added: ì[Pfizer] will bring forward major new product opportunities as aggressively as possible.î

Despite the downswing in stock value, and a consequent 15p upswing in the share price at AstraZeneca, the company has reassured investors that it will enhance total returns through ìdividends and share purchasesî. Pfizer's goal is to be able to bring up to six new products a year from 2010.

30th September 2008

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Six Degrees Medical Consulting

For over a decade, our medical communication services have helped pharmaceutical companies optimize their brand, disease and corporate objectives. Building...

Latest intelligence

PME Jan cover
AstraZeneca’s focus on diagnosing and managing chronic kidney disease
People living with chronic kidney disease are in urgent need of new and improved approaches to diagnosis and care...
Delphi Technique Virtual Co-creation: A Customer Story
How a client leveraged the Delphi technique to co-create a consensus statement and algorithm using virtual touchpoints....
AI healthcare
Three ways AI will change healthcare in the next decade
Looking forward, there is no doubt that AI will continue to take centre stage in global healthcare initiatives...

Infographics